Compound class:
Synthetic organic
Comment: The chemical structure for nispomeben was obtained from WHO proposed INN list 131 (August 2024). The INN record describes the compound as a non-opioid analgesic. It appears that this is the INN for Novaremed's clinical lead NRD.E1/NRD135S.E1 [1]. The mode of action of NRD.E1 involves inhibition of Lyn kinase phosphorylation, and not interactions with widely exploited pain-related targets (opioid, serotonin, GABA, NMDA or cannabinoid receptors, sodium or calcium channels). The exact mechanism of action remains to be determined.
|
|
No information available. |
Summary of Clinical Use ![]() |
As NRD135S.E1 this compound is a clinical candidate for the treatment of painful diabetic peripheral neuropathy [1]. |
Clinical Trials | |||||
Clinical Trial ID | Title | Type | Source | Comment | References |
NCT05480228 | EPPIC-Net: Novaremed Painful Diabetic Peripheral Neuropathy ISA | Phase 2 Interventional | Massachusetts General Hospital | ||
NCT02345291 | Effect of NRD135S.E1 in Peripheral Neuropathic Pain in Diabetic Patients | Phase 2 Interventional | Novaremed Ltd. | 1 |